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Abbreviations 
 ADR: Adverse drug reaction
 AW: Alcohol withdrawal
 BZD: Benzodiazepine
 CIWA-Ar: Clinical Institute 
Withdrawal Assessment for Alcohol, 
revised
 GABA: Gamma-aminobutyric acid
 ICU: Intensive care unit
 IRB: Institutional review board
 IV: Intravenous 
 LOS: Length of stay
 MINDS: Minnesota Detoxification 
Scale
 STT: Symptom-triggered therapy
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Objective 
 Discuss the outcomes of a fixed-dose protocol for the management of 
AW in a community hospital
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Background
 In the United States, 2 to 7% of heavy alcohol users admitted to the 
hospital for general medical care will develop severe AW
 The most dangerous complications of AW are delirium tremens and 
seizures
 Benzodiazepines are considered first-line therapy
o Alcohol is a central nervous system depressant which acts by modulation of 
GABA and glutamate activity
o BZDs modulate binding of GABA to its receptor, increasing chloride ion influx 
and causing an inhibitory effect similar to alcohol
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The Journal of Human Pharmacology and Drug Therapy. 2016; 36(7), 797-822.
Fixed-Dose versus STT
 Fixed-dose
o Historically has been used to 
manage AW
o BZDs are given at regular intervals
o Additional doses are given as 
needed depending on severity of the 
symptoms according to AW scale 
scoring
 STT
o BZDs are only administered when 
severity of symptoms necessitate, 
according to AW scale scoring
o Evidence shows that STT results in:
 Lower doses of BZDs
 Shorter BZD duration
 Decreased rate of severe AW
 Shorter duration of AW syndrome
 Decreased complications
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Purpose
 The purpose of this study was to evaluate the current BZD fixed-dose 
protocol and outline the transition to STT in the ICU
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Study Design
 Single center, IRB approved, 
retrospective chart review of patients 
treated for AW with a fixed-dose BZD 
protocol
 Study period: November 2017-
December 2019
 Inclusion 
o Admitted to an ICU 
o Treatment for AW 
o Use of BZDs
 Exclusion  
o Age < 18 years
o Pregnancy 
o Allergy to BZD
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Screening
9
A total of 90 patients 
were reviewed
46 patients met 
inclusion criteria
Excluded patients
• 39 BZD use for anxiety
• 5   BZD use as needed
Outcomes
 Primary outcomes
o Amount of BZD(s) used
• Chlordiazepoxide daily mg dose
o Duration of BZD therapy
• Days of BZD use 
o Time to symptom control
• Total days; beginning of symptoms to 
when symptoms were controlled
 Secondary outcomes
o BZD-related adverse effects
• Any BZD-related ADR such as 
somnolence, drowsiness, 
hypotension, or unresponsiveness 
• Reported by the nurse or physician
o LOS in the ICU
• Days spent in the ICU 
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Statistical Methods
 Descriptive statistics
o Mean 
• Duration of therapy
• Time to symptom control
o Median
• Daily BZD use
• LOS in the ICU
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Results: Primary Outcomes 
 Daily BZD(s) used: 
o 75 mg daily 
 Duration of BZD therapy: 
o 5.4 days
 Time to symptom control: 
o 4.25 days 
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65%
26%
9%
BZD Use
Asymptomatic After symptoms were controlled Similar duration of symptoms
Results: Secondary Outcomes
 BZD-related adverse effects
o Approximately 42% of the patients 
who experienced an ADR received 
BZDs while asymptomatic or after 
symptoms were controlled 
 LOS in the ICU
o Median: 3 days 
o Majority of patients were 
transferred to the floors 
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Additional Findings
 Only 21% of the prescribers used the AW PowerPlan
 Approximately 30% of patients had a CIWA-Ar score documented
o For patients with a documented CIWA-Ar score, most had low scores for 
which treatment was not indicated
o The use of CIWA-Ar did not necessarily correlate with the use of the 
PowerPlan
o In patients with a CIWA-Ar score, reassessment of the score was not 
conducted 
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Conclusions 
 The fixed-dose protocol led to patients receiving unnecessary treatment for 
AW
 Duration of BZD therapy was longer than time to symptom control, 
exposing patients to an extra day of unnecessary therapy
o A large percentage of these patients experienced an ADR 
 Areas for improvement for appropriate patient monitoring were identified, 
given the lack of use of the AW PowerPlan and poor documentation of 
CIWA-Ar scores
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Limitations
 Retrospective chart review
 Small sample size
 Information assessed based on documentation
 Multiple sedative medications utilized
 Challenging to assess ADRs in intubated patients
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Transition to STT
 Patients with AW will be treated using STT
 BZD of choice will be lorazepam oral or IV
 BZD will be administered based on a scale score (CIWA-Ar or MINDS)
 Score severity will determine BZD dose and monitoring parameters
o Monitoring will be conducted by nurses 
o Parameters will be pre-determined to ensure proper escalation and de-
escalation of therapy
 Education will be provided to physicians, nurses, and pharmacists 
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Assessment Question
 Which of the following outcomes is associated with fixed-dose 
benzodiazepine protocols?
A. Increased benzodiazepine use
B. Shorter duration of benzodiazepine use
C. Less sedation
D. Decreased length of stay
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Assessment Answer 
 Which of the following outcomes is associated with fixed-dose 
benzodiazepine protocols?
A. Increased benzodiazepine use
B. Shorter duration of benzodiazepine use
C. Less sedation
D. Decreased length of stay
19
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